Search
Alzheimer's Disease Paid Clinical Trials in South Carolina
A listing of 11 Alzheimer's Disease clinical trials in South Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 11 of 11
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Alzheimer's Disease
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
We’re searching for new treatments for Alpha-1 Liver Disease, but we need your help.
If you
- are between 18 to 75 years of age, inclusive
- Have a confirmed or suspected diagnosis of Alpha-1 Liver Disease
- OR have a family member with a confirmed or suspected diagnosis of Alpha-1
Liver Disease
You may be eligible to participate in a research opportunity evaluating the safety
and effectiveness of an investigational study drug.
If you
- are between 18 to 75 years of age, inclusive
- Have a confirmed or suspected diagnosis of Alpha-1 Liver Disease
- OR have a family member with a confirmed or suspected diagnosis of Alpha-1
Liver Disease
You may be eligible to participate in a research opportunity evaluating the safety
and effectiveness of an investigational study drug.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Recruiting
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
12/07/2023
Locations: Coastal Neurology PA, Port Royal, South Carolina
Conditions: Alzheimer's Disease
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/30/2023
Locations: Roper St. Francis Hospital, Charleston, South Carolina
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort.
If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
11/30/2023
Locations: Ralph H. Johnson VA Medical Center, Charleston, South Carolina +1 locations
Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
SUPPORT-D Intervention for Persons With Alzheimer's Disease and Their Caregivers
Recruiting
The purpose of this research is pilot test a nurse led intervention previously used in patients with pulmonary fibrosis and their caregivers in a new population (persons living with Mild Cognitive Impairment or Alzheimer's disease and their caregivers. The researchers hypothesize improving advanced care planning in this population will result in enhanced quality of life over illness trajectory and improve safety for community dwelling PWD/CG dyads. Findings from this study will inform additional... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Alzheimer Disease, Mild Cognitive Impairment
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
11/06/2023
Locations: Prisma Health Neurology, Columbia, South Carolina +1 locations
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
Recruiting
This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B.
In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants.
In the event that the stage gate for phase 2B is reached, the... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
11/01/2023
Locations: Lowcountry Center for Veterans Research (LCVR), Charleston, South Carolina
Conditions: Alzheimer Disease
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
10/16/2023
Locations: Care Access - Anderson, Anderson, South Carolina +7 locations
Conditions: Alzheimer Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial).
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
06/27/2023
Locations: Ralph H. Johnson VA Medical Center, Charleston, South Carolina +1 locations
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Musical Engagement of Brain LObes in Alzheimer's Disease Patients StudY
Recruiting
This is a randomized, cross-over study to measure global and clinical impact and level of arousal in subjects suffering from moderate to severe Alzheimer's disease when exposed to emotionally impactful music compared to control intervention.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
05/05/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Preventing Alzheimer's With Cognitive Training
Recruiting
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residentia... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
11/21/2022
Locations: Clemson University Institute for Engaged Aging, Seneca, South Carolina
Conditions: Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
Elucidating the Necessary Active Components of Training
Recruiting
Loss of independence, cognitive decline, and difficulties in everyday function are areas of great concern for older adults and their families. Cognitive training is one low cost, noninvasive training intervention that has repeatedly demonstrated reliable transfer effects to maintained cognition, everyday function, health, and most recently, a 29% reduction in incident dementia. Importantly, many of these everyday function effects are maintained across five to ten years including: maintained driv... Read More
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
05/04/2022
Locations: Clemson University Institute for Engaged Aging, Seneca, South Carolina
Conditions: Alzheimer Disease, Cognitive Change, Cognitive Impairment
1 - 11 of 11